Synonyms: BAY 2433334 | BAY2433334 | example 235 [WO2017005725A1]
Compound class:
Synthetic organic
|
|
References |
1. Heitmeier S, Visser M, Tersteegen A, Dietze-Torres J, Glunz J, Gerdes C, Laux V, Stampfuss J, Roehrig S. (2022)
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost, 20 (6): 1400-1411. [PMID:35289054] |
2. Jiminez Nunez E, Ackerstaff J, Rohrig S, Hillisch A, Meier K, Heitmeier S, Tersteegen A, Stampfuss J, Ellerbrock P, Melbom D et al.. (2017)
Substituted oxopyridine derivatives. Patent number: WO2017005725A1. Assignee: Bayer Pharma. Priority date: 09/07/2015. Publication date: 12/01/2017. |
3. Mailer RK, Renné T. (2022)
Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation. J Thromb Haemost, 20 (6): 1309-1311. [PMID:35596514] |
4. Roehrig S, Ackerstaff J, Jiménez Núñez E, Teller H, Ellerbrock P, Meier K, Heitmeier S, Tersteegen A, Stampfuss J, Lang D et al.. (2023)
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders. J Med Chem, 66 (17): 12203-12224. [PMID:37669040] |